Oxytocin vs bremelanotide

Oxytocin is an endogenous hormone with established obstetric uses; its sexual-function studies used particular nasal or vaginal preparations in distinct populations. Bremelanotide, also called PT-141, is a melanocortin-receptor agonist approved as Vyleesi for premenopausal women with acquired, generalized hypoactive sexual desire disorder. Separate trials cannot establish which is a better treatment for a shared patient group.

Research reviewed October 15, 2026. Educational information only.

Different receptor systems and indications

Oxytocin is a nine-residue hormone that binds the oxytocin receptor. In the uterus, it promotes contractions through changes in calcium signaling. The approved Pitocin injection is used for specified obstetric indications, including indicated induction or reinforcement of labor and control of postpartum bleeding. Those uses are separate from research into desire, social behavior or sexual function.

Bremelanotide, also called PT-141, is a cyclic seven-residue melanocortin-receptor agonist. The Vyleesi label identifies MC1 and MC4 among its receptor targets and says the precise mechanism improving hypoactive sexual desire disorder is unknown. Its approved indication concerns premenopausal women with acquired, generalized low desire that causes marked distress or interpersonal difficulty and is not explained by specified medical, relationship or medicine-related causes.

The main differences

Intranasal oxytocin did not establish a benefit over placebo in a small crossover trial

Muin and colleagues (2015) enrolled 30 premenopausal and postmenopausal women with sexual dysfunction in a randomized, double-blind crossover trial. Women used a nasal oxytocin preparation or placebo in separate eight-week periods, with a two-week washout before switching. Sexual-function questionnaire scores improved by 26% in the oxytocin period and 31% in the placebo period. Sexual-distress scores fell by 36% and 45%, respectively.

The analysis did not establish an added benefit from nasal oxytocin. Giving oxytocin first or second did not clearly change the result. Thus, the participants improved over time in both periods, and the small trial did not demonstrate an added benefit from oxytocin. This is not evidence that the treatments are equivalent or that every oxytocin preparation has no effect. The study’s mixed menopausal population and broad sexual-dysfunction eligibility also differ from the premenopausal HSDD population in the bremelanotide trials.

A vaginal-gel trial addressed postmenopausal vaginal atrophy

Abedi and colleagues (2020) studied 96 postmenopausal women with symptoms of vaginal atrophy and sexual dysfunction, assigning 48 to vaginal oxytocin gel and 48 to placebo. After eight weeks, the oxytocin group had better sexual-function questionnaire scores than the placebo group across the reported domains (P<0.0001). The abstract also describes improved vaginal maturation and pH measures, but does not give their numerical changes.

This positive report concerns a local gel and a condition involving vaginal tissue changes after menopause. Its public abstract does not provide a complete effect-size estimate, interval or adverse-event table. It neither overturns the separate nasal trial nor establishes how vaginal oxytocin compares with bremelanotide in premenopausal HSDD.

Bremelanotide improved desire and distress scores in RECONNECT

Kingsberg and colleagues (2019) reported two 24-week randomized, double-blind, placebo-controlled RECONNECT trials in premenopausal women with acquired, generalized HSDD. Of 1,267 randomized women,1,247 entered the safety population and 1,202 the modified intention-to-treat efficacy population. The main outcomes asked whether women reported more desire and less distress about low desire.

Compared with placebo, the pooled change favored bremelanotide by 0.35 points on the Female Sexual Function Index desire domain and by 0.33 points toward less distress on the specified distress item (both P<0.001). The prespecified count of satisfying sexual events did not establish an increase compared with placebo (integrated P=0.630). Later analyses of the proportion of encounters rated satisfying answer a different question and do not replace that count result.

The trials had unequal withdrawal, which matters when outcomes are missing. The subsequent open-label extension followed selected core-trial participants without a continuing placebo group and is not an independent randomized confirmation. Neither report compares bremelanotide directly with oxytocin.

Pharmacokinetics

The Pitocin injection label reports an oxytocin plasma half-life of about 1–6 minutes. That value describes disappearance from blood in the labeled systemic setting; it is not a measured duration of sexual effects from a nasal or vaginal preparation. A route changes where a compound is delivered and how it is absorbed, so the formulation must accompany an exposure statement.

After a single subcutaneous Vyleesi administration, the label reports a mean terminal bremelanotide half-life of approximately 2.7 hours, with a range of 1.9–4.0 hours. This describes the final decline in blood concentration. The label says the duration of efficacy after an administration is unknown. A longer plasma half-life therefore does not establish stronger desire, better sexual function or longer clinical benefit than oxytocin.

Safety depends on the preparation and the patient group

In RECONNECT, nausea occurred in 40.0% of bremelanotide-treated participants and 1.3% of placebo participants; flushing and headache were also more frequent. The Vyleesi label describes temporary blood-pressure increases, slower heart rate and focal darkening of the skin that did not always resolve. It contraindicates the product in uncontrolled hypertension or known cardiovascular disease. Slower stomach emptying can also affect absorption of oral medicines, with a specific concern for oral naltrexone.

Systemic oxytocin has its own major obstetric risks, including excessively strong uterine contractions and water intoxication under particular exposures. These label warnings concern supervised obstetric injection use; they are not measured adverse-event rates from the small nasal or vaginal sexual-function studies. Different populations, routes and completeness of harms reporting prevent a numerical safety ranking between the compounds.

Frequently asked questions

Profiles and related reading

References

1. Muin DA, Wolzt M, Marculescu R, Sheikh Rezaei S, Salama M, Fuchs C, Luger A, Bragagna E, Litschauer B, Bayerle-Eder M. Effect of long-term intranasal oxytocin on sexual dysfunction in premenopausal and postmenopausal women: a randomized trial. Fertility and Sterility. 2015;104(3):715–723.e4. doi:10.1016/j.fertnstert.2015.06.010.

   A 30-woman crossover trial found improvements during both oxytocin and placebo periods without an established treatment difference.

2. Abedi P, Zohrabi I, Ansari S, Maraghi E, Shakiba Maram N, Houshmand G. The Impact of Oxytocin Vaginal Gel on Sexual Function in Postmenopausal Women: A Randomized Controlled Trial. Journal of Sex & Marital Therapy. 2020;46(4):377–384. doi:10.1080/0092623X.2020.1738606.

   A separate vaginal-gel study in postmenopausal women with vaginal atrophy reported improved sexual-function scores; the population and route differ from nasal studies and RECONNECT.

3. Kingsberg SA, Clayton AH, Portman D, Williams LA, Krop J, Jordan R, Lucas J, Simon JA. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstetrics and gynecology. 2019;134(5):899–908. DOI: 10.1097/AOG.0000000000003500.

   Symptom scores improved while the specified event-count endpoint did not.

4. Simon JA, Kingsberg SA, Portman D, Williams LA, Krop J, Jordan R, Lucas J, Clayton AH. Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder. Obstetrics and gynecology. 2019;134(5):909–917. DOI: 10.1097/AOG.0000000000003514.

   Longer observations came from a selected group with substantial attrition.

5. Cosette Pharmaceuticals, Inc. VYLEESI (bremelanotide injection): Full prescribing information. DailyMed. Label revised March 2024; public record updated November 13, 2025; accessed October 15, 2026.

   Defines the approved population, acetate identity, subcutaneous pharmacokinetics and safety findings in their study contexts.

6. Pitocin (Oxytocin Injection, USP), Synthetic: Prescribing information. DailyMed. Accessed October 13, 2026.

   Defines obstetric uses, uterine and antidiuretic risks, route-dependent clinical response and the broad plasma half-life range.

7. Waltenspühl Y, Ehrenmann J, Vacca S, Thom C, Medalia O, Plückthun A. Structural basis for the activation and ligand recognition of the human oxytocin receptor. Nature Communications. 2022;13:4153. DOI: 10.1038/s41467-022-31325-0.

   The active receptor structure identifies the nine-residue ligand’s binding arrangement and disulfide-constrained ring.

8. National Library of Medicine. Bremelanotide. MeSH Supplementary Concept Data2026. Accessed October 15, 2026.

   Official vocabulary record links the PT-141 name to bremelanotide.